Glaxo Smith Kline results, Q2 2023
Net profit, assets, equity and cash flow for Q2 2023, against the same period a year earlier, from the published financial statements.
Net profit60.46 millionEGP · −91.8% vs the same period a year earlier
Total assets3.56 billionEGP · +11.7% vs the same period a year earlier
Shareholders' equity1.97 billionEGP · +13.7% vs the same period a year earlier
Operating cash flow302 millionEGP · +190.3% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Q2 2023 was about 60.46 million EGP, down −91.8% from 735 million EGP in Q2 2022.
- Total assets at the end of Q2 2023 were about 3.56 billion EGP, and shareholders' equity about 1.97 billion EGP.
- Operating cash flow for Q2 2023 was positive at 302 million EGP.
Key lines against the same period a year earlier
This periodQ2 2022Change
Net profit60.46 million735 million−91.8%
Gross profit877 million606 million+44.8%
Total assets3.56 billion3.19 billion+11.7%
Total liabilities1.59 billion1.46 billion+9.3%
Shareholders' equity1.97 billion1.73 billion+13.7%
Total liabilities and equity3.56 billion3.19 billion+11.7%
Operating cash flow302 million-335 million+190.3%
Investing cash flow85.5 million-242 million+135.4%
Financing cash flow-144 million-164 million+11.9%
Net change in cash243 million-740 million+132.9%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy